Solventum Hires Surgeon Dr. Ryan Egeland as Chief Medical Officer

Solventum has named Dr. Ryan Egeland, MD as its new chief medical officer.
 
In this role, Dr. Egeland will lead the company’s global medical and clinical affairs team. He will focus on fostering industry collaboration as well as identifying innovation and market expansion opportunities that intersect scientific rigor, clinical need, and commercial practicality.
 
Dr. Egeland comes to Solventum from Crossfire Medical, where he had served as the company’s CEO since 2022. He was previously head of strategic ventures and chief medical officer of Cardiovascular Systems Inc. (CSI).
 
Before his tenure at CSI, Dr. Egeland headed teams in business development & licensing, medical & scientific affairs, and product marketing at Medtronic, Covidien, and ev3. He trained in plastic and reconstructive surgery at Northwestern Memorial Hospital and has worked in major academic hospitals and private clinics.
 
“We are pleased to welcome Dr. Egeland to Solventum,” said executive VP and Medical Surgical group president Chris Barry. “With over two decades of experience in the research lab, operating room, and executive settings, his extensive experience and proven track record in clinical development strategy and execution will be invaluable as we advance our innovation pipeline and enhance patient care around the world.”
 
“I am thrilled to join Solventum. With products that offer profound clinical benefits and solutions that enhance provider efficiency and impact, we have a rare opportunity to help our customers enhance the patient experience and improve lives,” said Dr. Egeland. “Through partnership, innovation, and dedication to the patients we serve Solventum and our customers, together, will shape the future of healthcare.”
 
Last month, the company rolled out its V.A.C. peel and place dressing, an integrated dressing and drape that can be applied in under two minutes and worn for up to seven days.